Stock Events

Stock Events

Scynexis 

$1.13
39
+$0.09+8.65% Friday 15:30

Statistics

Day High
1.13
Day Low
1.04
52W High
1.22
52W Low
0.58
Volume
2,030
Avg. Volume
-
Mkt Cap
47.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.2
-0.05
0.1
0.25
Expected EPS
-0.123333
Actual EPS
N/A

Financials

-568.29%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
7.49MRevenue
-42.58MNet Income

Analyst Ratings

3Average Price Target
The highest estimate is 3.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0L49.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap153.13B
Pfizer is a global pharmaceutical company that competes with Scynexis in the development of antifungal and antibacterial drugs.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is involved in the development of anti-infective drugs, directly competing with Scynexis' focus on antifungal treatments.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, Inc. offers antifungal and antiviral therapies, making it a competitor in the infectious disease market.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca PLC has a portfolio that includes anti-infective drugs, competing with Scynexis in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments that compete with Scynexis' drug offerings.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc. competes in the antifungal space with its own range of products, posing competition to Scynexis.
Novartis
NVS
Mkt Cap297.35B
Novartis AG engages in the development of drugs to treat a wide range of infections, including fungal, competing with Scynexis.
AMGEN
AMGN
Mkt Cap189.22B
Amgen Inc. has a diverse biopharmaceutical portfolio that includes treatments for infections, competing with Scynexis.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb has a range of anti-infective drugs, making it a competitor in the same market as Scynexis.
Sanofi
SNY
Mkt Cap113.88B
Sanofi operates in the pharmaceutical sector with a focus on anti-infectives among other areas, competing with Scynexis.

About

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Show more...
CEO
Dr. David Gonzalez Angulo M.D.
Employees
18
Country
United States
ISIN
US8112922005

Listings

MU
DE
135A.MU
STU
DE
135A.STU
XNAS
US
SCYX
F
DE
135A.F

0 Comments

Share your thoughts

FAQ

What is Scynexis stock price today?▼
The current price of 0L49.LSE is $1.13 USD — it has increased by +8.65% in the past 24 hours. Watch Scynexis stock price performance more closely on the chart.
What is Scynexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scynexis stocks are traded under the ticker 0L49.LSE.
Is Scynexis stock price growing?▼
0L49.LSE stock has risen by +14.13% compared to the previous week, the month change is a +22.69% rise, over the last year Scynexis has showed a +21.37% increase.
What is Scynexis market cap?▼
Today Scynexis has the market capitalization of 47.42M
When is the next Scynexis earnings date?▼
Scynexis is going to release the next earnings report on May 07, 2026.
What were Scynexis earnings last quarter?▼
0L49.LSE earnings for the last quarter are 0.25 USD per share, whereas the estimation was 0.13 USD resulting in a +97.37% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scynexis revenue for the last year?▼
Scynexis revenue for the last year amounts to 7.49M USD.
What is Scynexis net income for the last year?▼
0L49.LSE net income for the last year is -42.58M USD.
How many employees does Scynexis have?▼
As of April 18, 2026, the company has 18 employees.
In which sector is Scynexis located?▼
Scynexis operates in the Other sector.
When did Scynexis complete a stock split?▼
The last stock split for Scynexis was on July 17, 2020 with a ratio of 1:10.
Where is Scynexis headquartered?▼
Scynexis is headquartered in Jersey City, United States.